Financial reports
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
18 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
8 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
20 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
Current reports
8-K
Departure of Directors or Certain Officers
24 Apr 24
8-K
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
22 Apr 24
8-K
Departure of Directors or Certain Officers
2 Apr 24
8-K
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
18 Mar 24
8-K
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett
4 Mar 24
8-K
Departure of Directors or Certain Officers
21 Feb 24
8-K
Neurogene Announces Business Update and 2024 Outlook
5 Jan 24
8-K
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
19 Dec 23
8-K
Other Events
6 Dec 23
8-K
Other Events
4 Dec 23
Registration and prospectus
S-8
Registration of securities for employees
20 Feb 24
425
Business combination disclosure
6 Dec 23
425
Business combination disclosure
4 Dec 23
425
Business combination disclosure
30 Nov 23
425
Business combination disclosure
5 Oct 23
S-4
Registration of securities issued in business combination transactions
18 Aug 23
425
Business combination disclosure
18 Jul 23
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
DEFA14A
Additional proxy soliciting materials
31 Mar 22
DEF 14A
Definitive proxy
31 Mar 22
DEFA14A
Additional proxy soliciting materials
31 Mar 21
DEF 14A
Definitive proxy
31 Mar 21
DEFA14A
Additional proxy soliciting materials
16 Apr 20
Other
EFFECT
Notice of effectiveness
14 Nov 23
SEC STAFF LETTER
SEC staff letter
13 Nov 23
CORRESP
Correspondence with SEC
8 Nov 23
CORRESP
Correspondence with SEC
8 Nov 23
CORRESP
Correspondence with SEC
18 Oct 23
UPLOAD
Letter from SEC
10 Oct 23
SEC STAFF LETTER
SEC staff letter
10 Oct 23
CORRESP
Correspondence with SEC
28 Sep 23
UPLOAD
Letter from SEC
18 Sep 23
EFFECT
Notice of effectiveness
19 May 22
Ownership
4
Rachel McMinn
14 Mar 24
4
Christine Mikail Cvijic
14 Mar 24
4
Stuart Cobb
14 Mar 24
144
Notice of proposed sale of securities
7 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
SC 13G
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G
Samsara BioCapital, L.P.
14 Feb 24
SC 13G
Cormorant Asset Management, LP
14 Feb 24